Abstract 9P
Background
In the era of immunotherapy (IT), radiomics emerged as a non-invasive tool to decode tumor immune microenvironment (TIME) and predict IT response. Intrinsic patient and tumor variability challenging the explainability of radiomic readouts might be overcome in preclinical settings. Thus, we aimed to develop a μCT radiomic platform in a CD8 T cell functionally manipulated orthotopic murine model, closely mimicking human head and neck cancer, to validate the biological reality of radiomics in assessing tumor infiltrating lymphocytes (TILs).
Methods
Set-up, training and validation experiments (N Tot = 50 C57BL/6 mice) were conducted as follows: submucosal injection of 0.5 x 106 TC1-luc cells in the right inner lip and generation of an orthotopic model of head and neck cancer (day [D] -7); tailored treatment consisting of irradiation [D0] ± anti-CD8 antibody [D3] to selectively enrich or deplete CD8+ TILs; in vivo preclinical imaging through Quantum FX μCT technology [D3, D4]; mice euthanasia and tumor sampling [D4], followed by immunohistochemical staining for CD8; μCT image pre-processing (voxel resampling, image discretization and delineation of the volume of interest) and radiomic features (RFs) extraction (pyradiomics).
Results
We developed and optimized an efficient quantitative μCT imaging approach. Overall, 106 μCT RFs (shape, first- and second- order) were extracted and correlated with distinct TIME. Following redundant feature elimination (Spearman correlation, cut-off = 0.99) and Z-score standardization, we identified 12 μCT-RFs differentially regulated in T CD8 enriched vs depleted TIME (P < 0.05, Mann Whitney). The statistical performance of our CD8 signature, documented in both training and validation sets, was further implemented when pooled data were analysed (P < 0.01). Finally, by applying a reconstruction algorithm, we obtained a 3D map of CD8+ TILs, which enabled us to correlate the spatial distribution of immune cells with μCT textural parameters.
Conclusions
Our results document the feasibility and accuracy of radiomics to detect dramatic changes in T cells within the TIME, thus providing effective radio-immune signatures potentially translatable into clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Gustave Roussy.
Funding
ESMO (Translational Research Fellowship; Recipient: Dr. Giulia Mazzaschi).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Presenter: Lidia Gatto
Session: Poster session 09
515P - A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
Presenter: Shu Zhou
Session: Poster session 09
516P - Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Presenter: Kristi Beshiri
Session: Poster session 09
517P - Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Presenter: Katherine Hewitt
Session: Poster session 09